36results about How to "Improve expression strength" patented technology

The invention provides a recombinant staphylococcal enterotoxin I oral preparation, the recombinant staphylococcal enterotoxin I has SEQ ID NO.1 amino acid sequence, and the oral preparation further comprises a pharmaceutical allowable drug excipient or a carrier. The oral preparation proves that the protein can enter the systemic blood circulation by penetrating epithelial cells on small intestine with the form of complete molecules and maintain the super-antigen activity for promoting the spleen lymphocyte proliferation and inhibiting the growth of tumor cells, as well as the application in the preparation of drugs for treating malignant tumors and other serious complications by the Caco-2 monolayer cell transmembrane transport test.

The invention provides a recombinant staphylococcal enterotoxin M oral preparation, the recombinant staphylococcal enterotoxin M has SEQ ID NO.1 amino acid sequence, and the oral preparation further comprises a pharmaceutical allowable drug excipient or a carrier. The oral preparation proves that the protein can enter the systemic blood circulation by penetrating epithelial cells on small intestine with the form of complete molecules and maintain the super-antigen activity for promoting the spleen lymphocyte proliferation and inhibiting the growth of tumor cells, as well as the application in the preparation of drugs for treating malignant tumors and other serious complications by the Caco-2 monolayer cell transmembrane transport test.

The invention discloses a chimeric antigen receptor (CAR) targeting CD32b, an immune effector cell modified by the CAR, a preparation method of the immune effector cell and application of the immune effector cell in inhibition of chronic lymphocytic leukemia for the first time. The invention provides a novel treatment scheme for refractory chronic lymphocytic leukemia.

The invention relates to a PiggyBac transposon system and application thereof, and particularly provides a nucleic acid construct which comprises the following elements: a transposon 3 '-terminal repetitive sequence, a first polyA sequence, an insulator sequence with a transcription termination function, a transposon 5'-terminal repetitive sequence, a transposase coding sequence and a promoter for controlling the expression of the transposase. The invention further provides a host cell or a pharmaceutical composition containing the nucleic acid construct and application of the host cell or the pharmaceutical composition.

The invention provides recombinant nitrile hydratase and application thereof in preparation of nicotinamide by coupling ion exchange resin, which comprises the following steps: by taking a concentrated solution of supernate obtained by ultrasonically crushing wet thalli obtained by fermentation culture of recombinant nitrile hydratase gene engineering bacteria as a catalyst and 3-cyanopyridine as a substrate, adding the ion exchange resin, and reacting at the temperature of between 20 and 30 DEG C to obtain the nicotinamide. The preparation method comprises the following steps: forming a reaction system by taking a phosphoric acid buffer solution with the pH value of 6-9 as a reaction medium, carrying out hydration reaction under the conditions of 20-30 DEG C and 100-1000rpm, and after the reaction is completed, separating and purifying the reaction liquid to obtain the product nicotinamide. The recombinant nitrile hydratase coupled ion exchange resin has the advantages of mild conditions, high efficiency, high chemical selectivity, regioselectivity and the like, the biological catalysis process has the characteristics of no toxicity, no pollution, low energy consumption and the like, the method is an environment-friendly synthesis method, 95% or more of nicotinic acid impurities are adsorbed, and the method is suitable for industrial production. The nicotinamide product with the purity of 99.99% or above is obtained.

The invention relates to application of a transcriptional regulatory factor expressed by eukaryotic genes, in particular to application of a transcriptional regulatory factor Ash1p of a constitutive promoter Pgap. The invention discloses application of Ash1p as a negative regulatory factor in improvement of protein expression in host cells. The amino acid sequence of the Ash1p is coded by an Ash1 gene with the nucleotide sequence of SEQ ID NO: 1; according to the application, expression of protein in host cells is improved by knocking out the Ash1 gene. According to the application disclosed by the invention, transcriptional regulation and control of the constitutive promoter Pgap in a pichia pastoris expression system can be enhanced by reducing a repression effect, so that the expression efficiency and the yield of target protein are improved.

The invention provides a recombinant staphylococcal enterotoxin O oral preparation, the recombinant staphylococcal enterotoxin O has SEQ ID NO.1 amino acid sequence, and the oral preparation further comprises a pharmaceutical allowable drug excipient or a carrier. The oral preparation proves that the protein can enter the systemic blood circulation by penetrating epithelial cells on small intestine with the form of complete molecules and maintain the super-antigen activity for promoting the spleen lymphocyte proliferation and inhibiting the growth of tumor cells, as well as the application in the preparation of drugs for treating malignant tumors and other serious complications by the Caco-2 monolayer cell transmembrane transport test.